CARsgen Therapeutics repurchases shares, total buyback hits 0.59% of mandate

On November 17, 2025, CARsgen Therapeutics Holdings Limited repurchased 112,000 ordinary shares on the Exchange at a volume-weighted average price of HK$17.573 per share. This transaction resulted in a decrease in issued shares (excluding treasury shares) by 0.019% from the previous balance.

The company's opening balance of issued shares (excluding treasury shares) as of November 11, 2025, was 575,086,905, with 2,855,500 treasury shares. Following the repurchase, the closing balance on November 17, 2025, stood at 574,974,905 issued shares and 2,967,500 treasury shares. The total number of issued shares remained at 577,942,405.

The repurchase was part of a mandate approved on May 22, 2025, authorizing the company to repurchase up to 57,543,590 shares. As of November 17, 2025, CARsgen Therapeutics has repurchased a total of 3,422,500 shares under this mandate, representing 0.5948% of the issued shares (excluding treasury shares) as at the date of the resolution. The aggregate price paid for the 112,000 shares repurchased on November 17, 2025, was HK$1,968,176, with individual prices ranging from HK$17.41 to HK$17.64.

Additionally, the disclosure indicates two previous instances of shares repurchased for cancellation but not yet cancelled: 250,000 shares on October 21, 2025, at HK$17.08, and 205,000 shares on October 23, 2025, at HK$16.58.